Pakistan Cabinet Approves Exemption for Import of Unregistered Life-Saving Drugs

Pakistan Grants Hospitals Exemption to Import Unregistered Life-Saving Drugs

In a decisive move to address critical drug shortages, Pakistan’s Federal Cabinet has approved a policy exemption allowing hospitals to import unregistered essential medications, including anti-cancer, cardiac, and other life-saving drugs.

Why the Exemption Matters

This exemption responds to urgent healthcare needs where delays in drug registration or limited commercial viability have restricted access to vital therapies. The policy ensures:

• Timely availability of life-saving treatments
• Non-commercial use strictly within hospitals and healthcare institutions
• Controlled access under professional supervision

Regulatory Safeguards in Place

To maintain safety and accountability, the following conditions apply:

• Pre-shipment approval from licensing authorities
• Exclusive institutional use—drugs cannot be sold in public markets
• Mandatory documentation of usage and distribution
• Customs clearance certificate required upon arrival

These measures align with international best practices, where regulators permit controlled access to unregistered drugs during exceptional circumstances.

Supporting Hospital Capacity Amid Bureaucratic Delays

The exemption is part of a broader effort to support hospitals facing bureaucratic and supply chain challenges. By enabling access to critical therapies, the government aims to:

• Prevent treatment disruptions
• Strengthen institutional healthcare delivery
• Ensure continuity of care for patients with urgent medical needs